Agalsidase alfa: A review of its use in the management of fabry disease

BioDrugs

Volumn 26, Issue 5, 2012, Pages 335-354

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Agalsidase alfa; Fabrys disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; AMIODARONE; CARBAMAZEPINE; CHLOROQUINE; CORTICOSTEROID; GABAPENTIN; GENTAMICIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G ANTIBODY; MONOBENZONE; PHENYTOIN; PLACEBO;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BRIEF PAIN INVENTORY; CEREBROVASCULAR ACCIDENT; CHILL; CHRONIC KIDNEY DISEASE; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DIZZINESS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME REPLACEMENT; FABRY DISEASE; FATIGUE; FEVER; FLUSHING; GLOMERULUS FILTRATION RATE; HEADACHE; HEARING LOSS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFUSION RELATED REACTION; INULIN CLEARANCE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QUALITY OF LIFE; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SWEAT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; ALPHA-GALACTOSIDASE; AMINO ACID SEQUENCE; ANIMALS; CHILD; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; PAIN; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84866068909     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11209690-000000000-00000     Document Type: Review

References (80)

1. Mehta A, Beck M, Eyskens F, et al. Fabry disease: A review of current management strategies. QJM Mon J Assoc Physicians 2010 Sep; 103 (9): 641-59
2. Hughes DA, Ramaswam U, Elliott P, et al. Guidelines for the diagnosis and management of Anderson-Fabry disease [online]. Available from URL: Http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-4118408.pdf [Accessed 2012 May 3]
3. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. AmJHumGenet 2006 Jul; 79 (1): 31-40
4. Ortiz A, Oliveira JP, Wanner C, et al. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 2008 Jun; 4 (6): 327-36
5. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: Eharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 2007 Oct; 47 (10): 1222-30
6. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003 Apr; 13 (4): 305-13
7. European Medicines Agency. European public assessment report for Replagal: scientific discussion [online]. Available fromURL: Http://www.ema.europa.eu [Accessed 2012 Apr 24]
8. European Medicines Agency. Replagal (agalsidase alfa): EU summary of product characteristics [online]. Available from URL: Http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000 /WC500053612.pdf [Accessed 2012 Apr 24]
9. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006 Mar; 51 (3): 180-8
10. Schiffmann R, Murray GJ, Treco D, et al. Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000 Jan 4; 97 (1): 365-70
11. Clarke JTR, West ML, Bultas J, et al. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007 Aug; 9 (8): 504-9
12. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease: Recommendations of a European expert group. J Inherit Metab Dis 2011 Apr; 34 (2): 509-14
13. Pastores GM, Boyd E, Crandall K, et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007 22 (7) 1920-1925.
14. Murray GJ, Anver MR, Kennedy MA, et al. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007 Mar; 90: 307-12
15. Schiffmann R, Kopp JB, Austin III IHA, et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001 Jun 6; 285 (21): 2743-9
16. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008 Feb; 94 (2): 153-8
17. Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006 Jul; 34 (1): 53-6
18. Schiffmann R, FloeterMK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003 Dec; 28 (6): 703-10
19. Moore DF, Scott LTC, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: Reversal by enzyme replacement therapy. Circulation 2001 Sep 25; 104 (13): 1506-12
20. Moore DF, Altarescu G, Ling GSF, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002
21. Feb; 33 (2): 525-31
22. Moore DF, Altarescu G, Herscovitch P, et al. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002 Jun 18; 2: 4
23. Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006 Feb; 21 (2): 345-54
24. Hajioff D, Goodwin S, Quiney R, et al. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003 Dec; 92: 28-30
25. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007 May; 18 (5): 1576-83
26. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009 May; 20 (5): 1132-9
27. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PloS One 2007 Jul; 2 (7): E598
28. Genzyme Corporation. Fabrazyme (agalsidase beta): US prescribing information [online]. Available from URL: Http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/103979s5135lbl.pdf [Accessed 2012 May 3]
29. European Medicines Agency. Fabrazyme (agalsidase beta): EU summary of product characteristics [online].Available fromURL: Http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000/WC500020547. pdf [Accessed 2012 May 3]
30. European Medicines Agency. Assessment report for Fabrazyme (agalsidase beta) [online]. Available from URL: Http://www.ema.europa.eu/docs/ Jul 10]
31. West M, Bichet DG, Casey R, et al. Prospective results of switching enzyme replacement therapy from agalsidase beta to agalsidase alfa in the Canadian Fabry Disease Initiative study [abstract no. 197]. 8th Annual Lysosomal Disease Network World Symposium; 2012 Feb 8-10; San Diego (CA
32. Sirrs S, Clarke JTR, Bichet DG, et al. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Mol Genet Metab 2010 Apr; 99 (4): 367-73
33. Canadian Fabry Research Consortium. Canadian Fabry Disease Initiative (CFDI) enzyme replacement therapy (ERT) study [ClinicalTrials.gov identifier NCT00455104]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://www.clinicaltrials.gov [Accessed 2012 May 4]
34. West M, LeMoine K, Bichet D, et al. A randomized controlled trial of enzyme replacement therapy in Fabry nephropathy: The Canadian Fabry Disease Initiative at year two [abstract]. Clin Ther 2010; 32 Suppl. C: S115-S6
35. West M, Bichet D, Casey R, et al. Agalsidase alfa and agalsidase beta have similar effects on outcomes in Fabry disease: Results from the Canadian Fabry Disease Initiative [abstract]. Mol Genet Metab 2011; 102: S46
36. Alpan-Goker O, Nedd K, Shankar S, et al. Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment-naïve or formerly treated with agalsidase beta [abstract]. Annual Clinical Genetics Meeting; 2012 Mar 27-31; Charlotte (NC
37. Goker-Alpan O, Nedd K, Shankar S, et al. Effect and tolerability of agalisdase alfa in patients with Fabry disease [abstract]. Society for the Study of Inborn Errors of Metabolism Annual Symposium; 2012 Sep 4-7; Birmingham
38. Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med. Epub 2012 Apr 12
39. Shire Human Genetic Therapies, Inc. Treatment protocol of Replagal for patients with Fabry disease [ClinicalTrials.gov identifier NCT01031173]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://www.clinicaltrials.gov [Accessed 2012 Aug 7]
40. Baehner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study. J Inherit Metab Dis 2003; 26 (7): 617-27
41. Kampmann C, Linhart A, Devereux RB, et al. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 2009 Sep; 31 (9): 1966-76
42. Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009 Jun; 11 (6): 441-9
43. Parini R, Rigoldi M, Santus F, et al. Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: Testing the effects with the Mainz Severity Score Index. Clin Genet 2008; 74 (3): 260-6
44. Thofehrn S, Netto C, Cecchin C, et al. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: A Brazilian experience. Ren Fail 2009 Oct; 31 ): 773-8
45. Dehout F, Roland D, Treille de Granseigne S, et al. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis 2004; 27 (4): 499-505
46. Ries M, Clarke JTR, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006 Sep; 118 (3): 924-32
47. Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010 May; 156 832-7
48. Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007 Jan; 96 122-7
49. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009 Dec 12; 374 (9706): 1986-96
50. Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy: A retrospective analysis from the Fabry outcome survey. Clin J Pain 2007
51. Jul/Aug; 23 (6): 535-42
52. Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006 Aug; 66 77-84
53. Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009 April; 29 (5): 353-61
54. Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. C J Am Soc Nephrol 2012 Jan; 7 (1): 60-9
55. Cybulla M, Walter KN, SchwartingA, et al. Kidney transplantation in patients with Fabry disease. Transpl Int 2009 Apr; 22 (4): 475-81
56. Hajioff D, Hegemann S, Conti G, et al. Agalsidase alpha and hearing in Fabry disease: Data from the Fabry Outcome Survey. Eur J Clin Invest 2006; 36: 663-7
57. Hoffmann B, Schwarz M, Mehta A, et al. Gastrointestinal symptoms in 342 patients with Fabry disease: Erevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007 Dec; 5 (12): 1447-53
58. Hughes DA, Barba Romero M-A, Hollak CEM, et al. Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS (the Fabry Outcome Survey). Mol Genet Metab 2011 Jul; 103: 207-14
59. Ramaswami U, Parini R, Pintos-Morell G, et al. Fabry disease in children and response to enzyme replacement therapy: Results from the Fabry Outcome Survey. Clin Genet 2012 May; 81 (5): 485-90
60. Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003; 26 (8): 787-94
61. Shire Human Genetic Therapies, Inc. Replagal- (agalsidase alfa): Canadian product monograph [online]. Available from URL: Http://www.shirecanada. com/en/shire-canada/Replagal-M-080521-En.pdf [Accessed 2012 May 1]
62. Schaefer RM, Tylki-Szymańska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: A systematic review of available evidence. Drugs 2009; 69 (16): 2179-205
63. Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther 2011; 5: 155-73
64. Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Therapy 2009 Feb; 9 (2): 255-61
65. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003 Feb 18; 138 (4): 338-46
66. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006 Sep; 8 (9): 539-48
67. Tøndel C, Bostad L, Hirth A, et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008 May; 51 (5): 767-76
68. Keating GM, Simpson D. Agalsidase beta: A review of its use in the management of Fabry disease. Drugs 2007; 67 (3): 435-55
69. Lubanda J-C, Anijalg E, Bzdú ch V, et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009 Apr; 11 (4): 256-64
70. Genzyme Corporation. Genzyme announces FDA approval of Framingham manufacturing plant [media release]. Available from URL: Http://www. businesswire.com/news/genzyme/20120123006531/en [Accessed 2012 May 4]
71. Linthorst GE, Germain DP, Hollak CEM, et al. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011 Jan; 102 (1): 99-102
72. Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 2012 Mar; 35 (2): 227-43
73. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol Genet Metab 2008 Jul; 94 (3): 319-25
74. Linthorst GE, Hollak CEM, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004 Oct; 66 (4): 1589-95
75. Brinks V, Richards S, Ruiz J, et al. Fabry disease antibody standardization initiative (FASI) [abstract]. Mol Genet Metab 2012; 105: S22-S3
76. Wendt S, Whybra C, Kampmann C, et al. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 2005; 28 (5): 787-8
77. Dehout F, Roland D, Henry F. Successful pregnancy in a patient with Fabry disease receiving enzyme replacement therapy [abstract]. Acta Paediatr 2006; 95 Suppl. 451: 137-8
78. Kalkum G, Macchiella D, Reinke J, et al. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. Eur J Obstet Gynecol Reprod Biol 2009 May; 144 (1): 92-3
79. Marshall J, Ashe KM, Bangari D, et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PloS One 2010; 5 (11): E15033
80. Abe A, Gregory S, Lee L, et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 2000 Jun; 105 (11): 1563-71